Cullinan Therapeutics, Inc.
Financials
Valuation Metrics
Cullinan Therapeutics, Inc.'s Market Cap is $1.37B. At end of 2025 it was $613M. Ranked #2282 of 3,121 in US market (top 73%), #919 of 1,463 on NASDAQ (top 63%), #172 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 65%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.37B | US#2,282/3,121 Sec#172/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-205M | US—/3,121 Sec—/266 |
| Total Assets | $364M | US#2,875/3,121 Sec#198/266 |
| Net Assets | $322M | US#2,493/3,121 Sec#154/266 |
| Employees | 109 | US#2,611/3,121 Sec#172/266 |
| Value | ||
| P/B | 4.27x | US#2,082/3,121 Sec#124/266 |
| FCF Yield | -11.59% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -63.62% | US#2,732/3,121 Sec#180/266 |
| ROA | -56.27% | US#3,008/3,121 Sec#225/266 |
| Financial Health | ||
| Debt Ratio | 13.06% | US#149/3,121 Sec#63/266 |
| Total Debt | $2M | US#2,960/3,121 Sec#235/266 |
| FCF | $-159M | US#2,733/3,121 Sec#185/266 |
| Cash | $79M | US#2,361/3,121 Sec#195/266 |
| Current Ratio | 8.42x | US#307/3,121 Sec#92/266 |
| Performance | ||
| 1Y Return | 260.20% | US#38/3,121 Sec#17/266 |
| 1M Return | 2.50% | US#674/3,121 Sec#68/266 |
| From 52W High | -7.89% | US#553/3,121 Sec#37/266 |
| 1Y MDD | -26.70% | US#1,170/3,121 Sec#65/266 |
| Trading | ||
| Volume | 724,902 shares | US#1,679/3,121 Sec#179/266 |
| Trading Value | $15M | US#2,073/3,121 Sec#163/266 |
| Per Share | ||
| EPS | $-3.18 | US—/3,121 Sec—/266 |
| BPS | $5.00 | US#2,285/3,121 Sec#129/266 |
Company Info
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.